1. H1N1 nanobody development and therapeutic efficacy verification in H1N1-challenged mice.
- Author
-
Hwang, Jaehyun, Jang, In-Young, Bae, Eunseo, Choi, Jaeseok, Kim, Jeong Hwan, Lee, Sang Beum, Kim, Jong Hyun, Lee, Jae Pil, Jang, Ho Young, Kim, Hyoung Tae, Lim, Jong-Woo, Yeom, Minjoo, Jang, Eunhee, Kim, Seong-Eun, Jeong, Hyoung Hwa, Kim, Jung Woo, Seong, Seung-Yong, Song, Daesub, and Na, Woonsung
- Subjects
- *
TREATMENT effectiveness , *MICE , *INFLUENZA viruses , *IMMUNOGLOBULINS , *SYMPTOMS , *H7N9 Influenza - Abstract
Influenza A virus causes numerous deaths and infections worldwide annually. Therefore, we have considered nanobodies as a potential treatment for patients with severe cases of influenza. We developed a nanobody that was expected to have protective efficacy against the A/California/04/2009 (CA/04; pandemic 2009 flu strain) and evaluated its therapeutic efficacy against CA/04 in mice experiments. This nanobody was derived from the immunization of the alpaca, and the inactivated CA/04 virus was used as an immunogen. We successfully generated a nanobody library through bio-panning, phage ELISA, and Bio-layer interferometry. Moreover, we confirmed that administering nanobodies after lethal doses of CA/04 reduced viral replication in the lungs and influenza-induced clinical signs in mice. These research findings will help to develop nanobodies as viral therapeutics for CA/04 and other infectious viruses. [Display omitted] • Through phage display technology using immunized Alpaca, H1 Nb-hIgG1 was developed. • H1 Nb-hIgG1 neutralize pandemic 2009 flu by binding to receptor binding domain. • Therapeutic efficacy of H1-Nb hIgG1 was confirmed in pandemic 2009 flu-infected mice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF